维普中文期刊产品整合服务
3篇 您的检索式:作者名="M.Wardlaw"
    题名 作者 年代 出处 被引量
1The molecular basis of thrombolysis and its clinical application in stroke显示文摘V.Murray B.Norrving P. A. G.Sandercock A.Terént J. M.Wardlaw P.Wester 2010Journal of Internal Medicine2010,,:1
2Imaging appearance of the symptomatic perforating artery in patients with lacunar infarction: Occlusion or other vascular pathology?显示文摘Joanna M.Wardlaw Martin S.Dennis Charles P.Warlow Peter A.Sandercock 2001Ann Neurol2001,,:1
3Clinical management of cerebral small vessel disease:a call for a holistic approach显示文摘Cerebral small vessel disease(SVD)is a common global brain disease that causes cognitive impairment,ischemic or hemorrhagic stroke,problems with mobility,and neuropsychiatric symptoms.The brain damage,seen as focal white and deep grey matter lesions on brain magnetic resonance imaging(MRI)or computed tomography(CT),typically accumulates'covertly'and may reach an advanced state before being detected incidentally on brain scanning or causing symptoms.Patients have typically presented to different clinical services or been recruited into research focused on one clinical manifestation,perhaps explaining a lack of awareness,until recently,of the full range and complexity of SVD.In this review,we discuss the varied clinical presentations,established and emerging risk factors,relationship to SVD features on MRI or CT,and the current state of knowledge on the effectiveness of a wide range of pharmacological and lifestyle interventions.The core message is that effective assessment and clinical management of patients with SVD,as well as future advances in diagnosis,care,and treatment,will require a more'joined-up'’approach.This approach should integrate clinical expertise in stroke neurology,cognitive,and physical dysfunctions.It requires more clinical trials in order to improve pharmacological interventions,lifestyle and dietary modifications.A deeper understanding of the pathophysiology of SVD is required to steer the identification of novel interventions.An essential prerequisite to accelerating clinical trials is to improve the consistency,and standardization of clinical,cognitive and neuroimaging endpoints.Una Clancy Jason P.Appleton Carmen Arteaga Fergus N.Doubal Philip M.Bath Joanna M.Wardlaw 2021Chinese Medical Journal2021,,2:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费